The $4 Billion AI Failure

What would you do if your company’s AI was supposed to change the world, but quietly couldn’t do the job?

In 2004, IBM built AI agent named Watson with one goal: to beat humans at Jeopardy!, the American television quiz show where contestants answer complex questions across dozens of topics. 7 years later, Watson defeated two of the show’s all-time champions which was a breakthrough moment for AI. IBM saw the opportunity and announced Watson’s next mission is to become an AI doctor that would help oncologists treat cancer patients. By 2013, IBM signed partnerships with the world’s top cancer centers, MD Anderson (University of North Carolina). The pitch was an AI that could read millions of medical papers, analyze patient records, and recommend the best cancer treatments faster than any human oncologist. It sounded like the future. Instead, it became one of the most expensive AI failures in history and one of the most important case studies every business leader should study before making their next AI investment.

$4B

Total Investment Lost

$62M

Spent at MD Anderson

0

Patients treated

The Story

Watson’s AI was built on Natural Language Processing (NLP) where it could read text, find patterns, and answer questions at superhuman speed. At MD Anderson Cancer Center in Houston, IBM spent years trying to build an “Oncology Expert Advisor”, an AI tool to help doctors treat leukemia patients. Watson was trained in thousands of medical cases, clinical guidelines, and research papers. 

The reality was not as good as expected. Hospital records had missing information, ambiguous terms, and inconsistent formatting. In one documented case, Watson confused “ALL”, the acronym used for both “Acute Lymphoblastic Leukemia” and “Allergy”. Two very different medical conditions, and the AI couldn’t tell them apart. 

After five years and $62 million, MD Anderson quietly let its contract with IBM expire. Not a single patient was ever treated using the system. IBM’s second Watson oncology partnership, Memorial Sloan Kettering, produced a product that launched globally. But many oncologists reported that the recommendations were simplistic, biased toward how doctors practiced and out of step with local guidelines. IBM eventually sold the entire Watson Health division to a private equity firm. IBM is not an outlier. The same pattern (overpromising AI, underinvesting in fundamentals, and losing stakeholder trust) is playing out right now in boardrooms and strategy meetings across every industry. 

This wasn't a healthcare problem. It was a leadership and execution problem, which means it can happen in any industry, at any company, at any scale.

The CEO Speaks

Unlike many executives who bury failures, IBM’s current CEO Arvind Krishna, named the mistakes directly through a series of interviews.

“I think that we were slow to monetize and slow to make the learnings from Watson consumable. The mistake we made was that I think we went after very big, monolithic answers, which the world was not ready to absorb. Beginning that way was the wrong approach.” - Arvind Krishna (CEO of IBM) at CNBC Interview, 2023

In the interview with TIME magazine in 2022, Krishna openly admitted that IBM’s biggest error was deploying AI straight into high-stakes, life-or-death decisions before the technology had earned anyone’s trust. His lesson was simple in hindsight, start small, in contained and low-risk areas, let users experience the value, build confidence gradually, and only then scale aggressively. Chasing moonshots from day one, he said, was the wrong move entirely. 

#QuestionToReflect: Ask yourself this question before your next AI rollout, “Have we earned the trust of the people who will use this?"

Speaking to The Register in 2022, Krishna noted that winning over hospitals required doctors and nurses at the table, not IBM’s enterprise sales team. The technology may have been impressive on paper, but if the people championing it can’t speak the language of their end users, adoption was never going to happen. 

#QuestionToReflect: Ask yourself this question to prevent misalignment, “Who is championing your AI internally?”

The Lesson #1: Don’t Go After Moonshots First

IBM tried to solve one of the hardest problems on earth with AI that wasn’t ready for it. Krishna’s lesson: start small, in low-stakes areas, build trust with users, then scale. Deploying AI into high-stakes decisions before it is proven is how you burn $4 billion.

Leader’s action: Identify one low-risk, high-visibility process in your organization where AI can prove its value in 90 days.

The Lesson #2: Messy Data Kills Good AI

Watson’s NLP was technically advanced, but it was only as good as the data it received. Messy, unstructured, inconsistent hospital records broke at every turn. The hard truth is that AI implementation is 80% of a data problem. It’s time for you to ask this question before any AI investment, "Is our data actually ready for this?"

Leader’s action: Before any AI investment, try to audit your data to see if it’s ready. 

The Lesson #3: Domain Mismatch Kills Adoption

IBM’s sales team were enterprise tech experts, not oncologists. The people deploying the AI had no credibility with the people being asked to use it. No matter how good your AI is, if you can’t speak the language of your end users, it won’t be used. 

Leader’s action: Map out who will champion AI in each department.

If you're a leader in evaluating AI for your organization, IBM's story is the most expensive case study you'll never have to pay for. IBM had the budget, the engineers, and the ambition. What they didn't have was a clear framework for deploying AI the right way. The same traps are waiting for any organization that rushed into AI without the right foundation. Whether you are in financial services, retail, education, or manufacturing, the pattern is the same. The good news is that foundations can be learned.